Skip to main content

04-17-2019 | Nephropathy | Podcast | Article

Nephrologist expert commentary: The CREDENCE trial

Andrew Frankel, Consultant Physician and Nephrologist at Imperial College Healthcare NHS Trust, tells medwireNews about the rationale and key findings of the CREDENCE trial, and discusses the potential benefits of SGLT2 inhibitors beyond type 2 diabetes (9:45).

More content in this series

Related topics

More on this topic